Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

Rhea-AI Summary

Anteris Technologies Global Corp. (NASDAQ/ASX: AVR) has appointed David Roberts and Gregory Moss to its Board of Directors, while Dr. Wenyi Gu has resigned. Roberts, currently President of LeMaitre Vascular (NASDAQ: LMAT) since 2007, brings extensive healthcare executive experience and financial expertise. Moss serves as Chief Business and Legal Officer at Evommune and previously led Kadmon's $1.9B acquisition by Sanofi. These U.S.-based appointments follow Anteris' Q4 2024 NASDAQ listing and come as the company prepares to launch its DurAVR® THV global pivotal clinical trial (PARADIGM Trial) in Q3 2025. The strategic board changes aim to strengthen Anteris' leadership as it pursues U.S. and EMA licensure for its DurAVR® THV treatment for aortic stenosis patients.

Positive

• Addition of two experienced U.S.-based healthcare executives to the board strengthens leadership
• David Roberts brings extensive experience as President of NASDAQ-listed LeMaitre Vascular
• Gregory Moss brings valuable M&A expertise, having led Kadmon's $1.9B acquisition by Sanofi
• Strategic timing with upcoming PARADIGM Trial launch in Q3 2025

Negative

• None.

News Market Reaction

-0.37%

1 alert

-0.37% News Effect

On the day this news was published, AVR declined 0.37%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership Capacities

MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director.

“On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company” commented John Seaberg, Chairman of Anteris. “On the heels of our Q4 2024 listing onto NASDAQ, and as we ramp-up activities to launch the DurAVR^® THV global, pivotal clinical trial (the "PARADIGM Trial"), we are excited to enhance the leadership team with two highly accomplished, U.S. based, healthcare executives as the company transitions to its next phase of growth. I also wish to extend gratitude to Dr. Gu for his commitment and contributions to the company over the course of his tenure as a member of the Board and wish him well on his future endeavors.”

Mr. David Roberts is currently President of LeMaitre Vascular, Inc. (NASDAQ: LMAT), a position he has held since 2007. He joined LeMaitre in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000. Prior to LeMaitre, Mr. Roberts served as Vice President of Development for BUCA, Inc. from 1994 to 1997, and prior to that as Associate of HarbourVest Partners from 1992 to 1994. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts serves as a director of LeMaitre Vascular, Inc., Lexington Medical, Inc. and Parasole Restaurant Holdings, Inc.

Mr. Gregory Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune, Inc. Prior to Evommune, Mr. Moss served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon’s $1.9 billion acquisition in 2021. Prior to joining Kadmon in 2012, Mr. Moss served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes. Mr. Moss currently serves on the board of Vitls, Inc. Mr. Moss earned a BA and an LLB from Macquarie University, Australia, and is a member of the Bar Associations of New York, USA, and New South Wales, Australia, with admissions before the Supreme Court of the United States of America; Southern District of New York; Supreme Court of New South Wales, Australia; and High Court of Australia.

Mr. Roberts and Mr. Moss will help guide Anteris through its next phase of growth, with the upcoming global pivotal PARADIGM study in 3Q2025 towards the ultimate U.S. and EMA licensure of the DurAVR^® THV for patients with aortic stenosis.

About Anteris

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris’ lead product, the DurAVR^® Transcatheter Heart Valve (THV), was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR^® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR^® THV is made using a single piece of molded ADAPT^® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT^® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR^® THV System is comprised of the DurAVR^® valve, the ADAPT^® tissue, and the balloon-expandable ComASUR^® Delivery System.

For more information:

Investor Relations  investor@anteristech.com Debbie Ormsby Anteris Technologies Global Corp. +61 1300 550 310 | +61 7 3152 3200

Investor Relations (US) mchatterjee@bplifescience.com Malini Chatterjee, Ph.D. Blueprint Life Science Group +1 917 330 4269

Website X Facebook LinkedIn

www.anteristech.com @AnterisTech www.facebook.com/anteristech https://www.linkedin.com/company/anteristech

FAQ

Who are the new board members appointed to Anteris Technologies (AVR)?

Anteris Technologies appointed David Roberts, current President of LeMaitre Vascular, and Gregory Moss, Chief Business and Legal Officer of Evommune, to its Board of Directors.

What is the significance of these appointments for Anteris (AVR)?

The appointments strengthen Anteris' leadership with U.S.-based healthcare executives as the company prepares for its DurAVR® THV global pivotal trial and follows its recent NASDAQ listing.

What is David Roberts' background and experience?

David Roberts has been President of LeMaitre Vascular since 2007, previously serving as CFO and VP of Business Development. He holds an MBA from Stanford and serves on multiple corporate boards.

What is Gregory Moss' experience in healthcare leadership?

Gregory Moss is Chief Business and Legal Officer at Evommune and previously led Kadmon's legal and business development operations, including its $1.9B acquisition by Sanofi in 2021.

When is Anteris (AVR) planning to launch its PARADIGM Trial?

Anteris is planning to launch the DurAVR® THV global pivotal PARADIGM clinical trial in the third quarter of 2025.